In the last trading session, 1.2 million FibroGen Inc (NASDAQ:FGEN) shares changed hands as the company’s beta touched 0.71. With the company’s per share price at $0.44 changed hands at $0.01 or 2.86% during last session, the market valuation stood at $44.27M. FGEN’s last price was a discount, traded about -536.36% off its 52-week high of $2.80. The share price had its 52-week low at $0.18, which suggests the last value was 59.09% up since then. When we look at FibroGen Inc’s average trading volume, we note the 10-day average is 1.39 million shares, with the 3-month average coming to 3.60 million.
Analysts gave the FibroGen Inc (FGEN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended FGEN as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. FibroGen Inc’s EPS for the current quarter is expected to be -0.2.
FibroGen Inc (NASDAQ:FGEN) trade information
Instantly FGEN was in green as seen at the end of in last trading. With action 18.47%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -17.03%, with the 5-day performance at 18.47% in the green. However, in the 30-day time frame, FibroGen Inc (NASDAQ:FGEN) is -3.66% down. Looking at the short shares, we see there were 5.3 million shares sold at short interest cover period of 0.77 days.
The consensus price target for the stock as assigned by Wall Street analysts is 28, meaning bulls need an upside of 98.43% from its current market value. According to analyst projections, FGEN’s forecast low is 28 with 28 as the target high. To hit the forecast high, the stock’s price needs a -6263.64% plunge from its current level, while the stock would need to soar -6263.64% for it to hit the projected low.
FibroGen Inc (FGEN) estimates and forecasts
Year-over-year growth is forecast to reach 20.37% up from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 24.91M. The company’s revenue for the corresponding quarters a year ago was 27.14M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -8.21%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -23.23%. The 2025 estimates are for FibroGen Inc earnings to increase by 72.60%, but the outlook for the next 5-year period is at 49.32% per year.
FGEN Dividends
FibroGen Inc is expected to release its next quarterly earnings report on 2024-Nov-11.
FibroGen Inc (NASDAQ:FGEN)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.89% of FibroGen Inc shares while 36.95% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 37.28%. There are 36.95% institutions holding the FibroGen Inc stock share, with PRIMECAP MANAGEMENT CO/CA/ the top institutional holder. As of 2024-06-30, the company held 13.6785% of the shares, roughly 13.66 million FGEN shares worth $12.19 million.
ARMISTICE CAPITAL, LLC holds the second largest percentage of outstanding shares, with 8.9508% or 8.94 million shares worth $7.97 million as of 2024-06-30.
